Estrone-3-sulphate, a potential novel ligand for targeting breast cancers.
The current study investigates the potential of estrone-3-sulphate (E3S) as a ligand for targeting Organic Anion Transporting Polypeptides (OATP), a family of membrane associated uptake transporters, for detection and diagnosis of hormone dependent breast cancers. E3S, an OATP substrate, is a predom...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3661587?pdf=render |
id |
doaj-d2fd71360aa046be9e845bc15a0166a2 |
---|---|
record_format |
Article |
spelling |
doaj-d2fd71360aa046be9e845bc15a0166a22020-11-25T02:56:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6406910.1371/journal.pone.0064069Estrone-3-sulphate, a potential novel ligand for targeting breast cancers.Nilasha BanerjeeHumphrey FongeAndrew MikhailRaymond M ReillyReina BendayanChristine AllenThe current study investigates the potential of estrone-3-sulphate (E3S) as a ligand for targeting Organic Anion Transporting Polypeptides (OATP), a family of membrane associated uptake transporters, for detection and diagnosis of hormone dependent breast cancers. E3S, an OATP substrate, is a predominant source of tumour estradiol in post-menopausal patients. To assess the potential of E3S as a ligand, distribution of exogenous E3S was determined at the whole body, tumour and cellular levels in murine models of hormone-dependent (MCF-7) and independent (MDA-MB-231) breast cancers. The highest levels of tumour uptake were observed at 6 h post injection (p.i) with significant difference (p = 0.04) between the level in MCF-7 (13.9±3.1%ID/g) and MDA-MB-231 (10.4±1.1%ID/g) (%ID/g: percentage of the total injected dose per gram tissue). The highest tumour-to-blood ratios (MCF-7∶7.4±1.2; MDA-MB-231∶9.1±2.1) were observed at 48 p.i., and highest tumour-to-muscle ratios (MCF-7∶10.7±1.5; MDA-MB-231∶3.8±0.7) were observed at 6 h p.i. Analogous to total tumour uptake, ex vivo tumour cell uptake at 2 h p.i. was 6 fold higher in MCF-7 in comparison to MDA-MB-231 tumour cells. Blocking studies, conducted by pre-administration of 100-fold excess E3S, resulted in significantly lower (MCF-7: p = 0.01; MDA-MB-231: p = 0.02) tumour uptake in both xenograft models, suggesting the involvement of an active carrier-mediated process. The expression of OATP1A2 was detected in tumour sections from both xenografts, with significantly higher expression (p = 0.002) in the MCF-7 xenografts. Overall, the higher tumour uptake and tumour-to-muscle ratio, alongside the higher expression of OATP1A2, in the MCF-7 xenograft model suggests the potential of E3S to serve as a novel ligand for targeting hormone dependent breast cancers.http://europepmc.org/articles/PMC3661587?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nilasha Banerjee Humphrey Fonge Andrew Mikhail Raymond M Reilly Reina Bendayan Christine Allen |
spellingShingle |
Nilasha Banerjee Humphrey Fonge Andrew Mikhail Raymond M Reilly Reina Bendayan Christine Allen Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS ONE |
author_facet |
Nilasha Banerjee Humphrey Fonge Andrew Mikhail Raymond M Reilly Reina Bendayan Christine Allen |
author_sort |
Nilasha Banerjee |
title |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
title_short |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
title_full |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
title_fullStr |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
title_full_unstemmed |
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
title_sort |
estrone-3-sulphate, a potential novel ligand for targeting breast cancers. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
The current study investigates the potential of estrone-3-sulphate (E3S) as a ligand for targeting Organic Anion Transporting Polypeptides (OATP), a family of membrane associated uptake transporters, for detection and diagnosis of hormone dependent breast cancers. E3S, an OATP substrate, is a predominant source of tumour estradiol in post-menopausal patients. To assess the potential of E3S as a ligand, distribution of exogenous E3S was determined at the whole body, tumour and cellular levels in murine models of hormone-dependent (MCF-7) and independent (MDA-MB-231) breast cancers. The highest levels of tumour uptake were observed at 6 h post injection (p.i) with significant difference (p = 0.04) between the level in MCF-7 (13.9±3.1%ID/g) and MDA-MB-231 (10.4±1.1%ID/g) (%ID/g: percentage of the total injected dose per gram tissue). The highest tumour-to-blood ratios (MCF-7∶7.4±1.2; MDA-MB-231∶9.1±2.1) were observed at 48 p.i., and highest tumour-to-muscle ratios (MCF-7∶10.7±1.5; MDA-MB-231∶3.8±0.7) were observed at 6 h p.i. Analogous to total tumour uptake, ex vivo tumour cell uptake at 2 h p.i. was 6 fold higher in MCF-7 in comparison to MDA-MB-231 tumour cells. Blocking studies, conducted by pre-administration of 100-fold excess E3S, resulted in significantly lower (MCF-7: p = 0.01; MDA-MB-231: p = 0.02) tumour uptake in both xenograft models, suggesting the involvement of an active carrier-mediated process. The expression of OATP1A2 was detected in tumour sections from both xenografts, with significantly higher expression (p = 0.002) in the MCF-7 xenografts. Overall, the higher tumour uptake and tumour-to-muscle ratio, alongside the higher expression of OATP1A2, in the MCF-7 xenograft model suggests the potential of E3S to serve as a novel ligand for targeting hormone dependent breast cancers. |
url |
http://europepmc.org/articles/PMC3661587?pdf=render |
work_keys_str_mv |
AT nilashabanerjee estrone3sulphateapotentialnovelligandfortargetingbreastcancers AT humphreyfonge estrone3sulphateapotentialnovelligandfortargetingbreastcancers AT andrewmikhail estrone3sulphateapotentialnovelligandfortargetingbreastcancers AT raymondmreilly estrone3sulphateapotentialnovelligandfortargetingbreastcancers AT reinabendayan estrone3sulphateapotentialnovelligandfortargetingbreastcancers AT christineallen estrone3sulphateapotentialnovelligandfortargetingbreastcancers |
_version_ |
1724714109052649472 |